The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome - PubMed (original) (raw)

The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome

Samantha Portis et al. Int J Physiol Pathophysiol Pharmacol. 2012.

Abstract

Fragile X syndrome (FXS), one of the most common genetic causes of autism, results from a loss of fragile X mental retardation protein (FMRP) expression. At the molecular level, abnormal neurodevelopment is thought to result from dysregulated protein synthesis of key neural synaptic proteins, however recent evidence suggests broader roles for this protein including glutamate signaling, memory, and regulation of the critical serine/threonine regulatory kinase, glycogen synthase kinase-3 (GSK-3). In this review, genetic and molecular features of FXS are detailed in the context of FXS neuropathology. Additionally, potential mechanisms by which FMRP silencing impacts GSK-3 and GSK-3-associated signaling pathways are discussed. As GSK-3 signaling represents a central regulatory node for critical neurodevelopmental pathways, understanding how FXS results from FMRP-mediated GSK-3 dysregulation may provide novel therapeutic targets for disease-modifying interventions for FXS and related ASDs.

Keywords: Glycogen synthase kinase; flavonoids; fragile X; lithium; microglia; neuroinflammation; trinucucleotide repeat.

PubMed Disclaimer

Figures

Figure 1

Figure 1

GSK3 regulates a variety of pathways involved in neurodevelopment. Active GSK3 regulates the canonical Wnt pathway by remaining bound to the Wnt/β-catenin destruction complex that includes APC and Axin. This complex targets β-catenin for proteasomal degradation. Inhibitory phosyphorylation of GSK3 releases β-catenin from the complex. It is then recruited to the nucleus by TCF/LEF where it induces gene transcription. GSK3β is known to phosphorylate and inhibit Notch, resulting in the inhibition of many Notch target genes. This inhibitory phosphorylation is reversed when Wnt1 is present. Inhibitory phosphorylation is induced by a number of kinases. The PI3/Akt pathway regulates GSK-3 activity by inducing inhibitory serine-phosphorylation. FMRP is deficient in Fragile X syndrome and is normally responsible for regulating mRNA transcription of metabotropic glutamate receptor-5 (mGluR5) and GSK3. It has been shown that inhibition of mGluR5 leads to the inhibition of GSK3. In addition to regulating neurodevelopmental pathways, it has been shown that GSK3 is also involved in pathways that promote inflammation. GSK3 induces IL-6 production, leading to the subsequent phosphorylation of Jak2/STAT3.

Similar articles

Cited by

References

    1. Martin JP, Bell J. A Pedigree of Mental Defect Showing Sex-Linkage. J Neurol Psychiatry. 1943;6:154–157. - PMC - PubMed
    1. Penagarikano O, Mulle JG, Warren ST. The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet. 2007;8:109–129. - PubMed
    1. Koukoui SD, Chaudhuri A. Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome. Brain Res Rev. 2007;53:27–38. - PubMed
    1. Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci. 2006;9:1221–1225. - PubMed
    1. Hagerman RJ, Ono MY, Hagerman PJ. Recent advances in fragile X: a model for autism and neurodegeneration. Curr Opin Psychiatry. 2005;18:490–496. - PubMed

LinkOut - more resources